StockIQ.techResMed Inc. (RMD) Stock Analysis
Free AI-powered analysis and research for ResMed Inc. stock
Sector: Healthcare
RMD snapshot
Data as of 4 Nov 2026 close. Updated daily.
ResMed Inc. scores 80/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 61% of its 52-week range, down 2.5% over the past year. Latest reported figures show a profit margin of 26.9%, return on equity of 24.3% and revenue growth of +8.6%.
What is driving the score
- RSI Neutral: +5
- Uptrend: +5
- MACD Bearish: -8
- Excellent Profit Margin (26.9%): +10
- Low Debt (0.13 D/E): +8
- Strong Liquidity (3.10 Current Ratio): +8
- Excellent ROE (24.3%): +8
- High P/B (5.48): -5
- Above MA200: +4
- Underperforming (-2.5% over 1 year): -5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full RMD report
ResMed Inc. (RMD) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze RMD Now →📰 Latest Update
ResMed: 3 Key Takeaways for Long-Term Investors
Mon, November 2, 2026 at 9:33 AM UTC 4 min read
ResMed (RMD) reported 7% core revenue growth and expanding gross margins in its Q1 fiscal year 2027 earnings call, driven by manufacturing efficiencies and supply chain improvements. The company is focusing on its core medical devices and digital health software after selling its noncore MatrixCare business, using the proceeds for share repurchases. Management highlighted increased demand for sleep therapy, particularly among patients using GLP-1 weight-loss drugs, which supports longer therapy adherence and consistent mask purchases.